MedPath
HSA Approval

LUNSUMIO CONCENTRATE FOR SOLUTION FOR INFUSION 1MG/ML

SIN17001P

LUNSUMIO CONCENTRATE FOR SOLUTION FOR INFUSION 1MG/ML

LUNSUMIO CONCENTRATE FOR SOLUTION FOR INFUSION 1MG/ML

May 8, 2024

ROCHE SINGAPORE PTE. LTD.

Regulatory Information

HSA regulatory responsibility and product classification details

Regulatory Responsibility

RegistrantROCHE SINGAPORE PTE. LTD.

Product Classification

D
Drug Type
Therapeutic
F
Forensic Class
Prescription Only
HSA Singapore Classification

Formulation Information

INFUSION, SOLUTION CONCENTRATE

INTRAVENOUS

Medical Information

L01FX25

Manufacturer Information

ROCHE SINGAPORE PTE. LTD.

Genentech, Inc.

Active Ingredients

Mosunetuzumab

1 mg/ml

Mosunetuzumab

Documents

Package Inserts

Lunsumio infusion PI.pdf

Approved: May 8, 2024

Download

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.

LUNSUMIO CONCENTRATE FOR SOLUTION FOR INFUSION 1MG/ML - HSA Approval | MedPath